Discover how to optimize employee wellbeing by addressing mental, physical, financial, and social challenges, as discussed by Paula Allen at the 20th TELUS Health Annual Conference.
Read article
Error - something went wrong!
Receive insights on the latest healthcare trends delivered right to your inbox.
Thank you!
Discover how workplace accommodations and quicker access to effective therapies can significantly boost productivity for employees with migraines.
Read article
Generative artificial intelligence (AI) is a "transformative milestone" that will change our world on the scale of technological developments such as harnessing electricity, creating the semiconductor
Read article
Diabetes, depression, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis are among the conditions driving the utilization of private drug plans in recent years.
Read article
Explore presentations from the TELUS Health Annual Conference 2024 for cutting-edge insights.
Read article
For the first time, the annual Drug Trends Report casts back to include claims data from 2008, when TELUS Health began compiling data to share with the benefits industry...
Read article
In its 2024 Drug Pipeline report, TELUS Health draws attention to 12 new drugs due to their expected budget impact on private drug plans.
Read article
For two decades, TELUS Health has been at the forefront of healthcare innovation. As we gear up for our 20th virtual annual conference, we're anticipating another record-breaking turnout.
Read article
Pharmacogenomic (PGx) testing may have the potential to revolutionize prescription drug use in Canada by tailoring treatment to individual patients and save public and private payers billions...
Read article
In a groundbreaking collaboration, TELUS Health and Clinia have revealed an exclusive strategic partnership, marking the dawn of a new era in healthcare navigation and personalized care journeys.
Read article
TELUS Health’s 2023 Category Watch closely examines disruption in the drug categories of diabetes, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis.
Read article
Unlock the potential of DE&I in the modern workplace by reshaping benefits to create loyalty, inclusivity, and specialized support for all employees
Read article
Half of plan members reported that the coverage level of at least one of their health benefits limited their ability to seek treatment...
Read article
Unlock valuable insights into the ever-changing world of private drug plans.
Read article
Relatively new in Canada, cost-effectiveness analysis focuses on identifying therapies that may not be the most economical but that represents good value for money.
Read article
Discover the profound impact of the pandemic on workplace mental health and learn why employers must address it. Here's how employers can help create healthier workplaces to inspire future leaders.
Read article
Industry experts share their insights into how real-world evidence (RWE) can enhance reimbursement decision-making for private drug plans.
Read article
Diabetes, asthma, depression and attention deficit hyperactivity disorder (ADHD)—these categories are driving utilization and spend in private drug plans. Here's what private payors need to know.
Read article
The key drivers of change in spending by private drug plans in 2022 can be boiled down to two words: biosimilars and diabetes.
Read article
Presentations from April 26 and May 3, 2023.
Read article
Loading more...
